{"id":919713,"date":"2025-12-15T09:44:15","date_gmt":"2025-12-15T14:44:15","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/nasdaq-tlx-investor-alert-berger-montague-advises-telix-pharmaceuticals-ltd-nasdaq-tlx-investors-of-a-january-9-2026-deadline\/"},"modified":"2025-12-15T09:44:15","modified_gmt":"2025-12-15T14:44:15","slug":"nasdaq-tlx-investor-alert-berger-montague-advises-telix-pharmaceuticals-ltd-nasdaq-tlx-investors-of-a-january-9-2026-deadline","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/nasdaq-tlx-investor-alert-berger-montague-advises-telix-pharmaceuticals-ltd-nasdaq-tlx-investors-of-a-january-9-2026-deadline\/","title":{"rendered":"NASDAQ: TLX INVESTOR ALERT: Berger Montague Advises Telix Pharmaceuticals Ltd. (NASDAQ: TLX) Investors of a January 9, 2026 Deadline"},"content":{"rendered":"
\n

PR Newswire<\/p>\n<\/p><\/div>\n

\n

\n PHILADELPHIA<\/span>, Dec. 15, 2025<\/span> \/PRNewswire\/ —\u00a0National plaintiffs’ law firm Berger Montague PC<\/a><\/u>\u00a0announces that a class action lawsuit has been filed against Telix Pharmaceuticals Ltd. (NASDAQ: TLX)<\/b> (“Telix” or the “Company”) on behalf of investors who purchased Telix securities during the period of\u00a0February 21, 2025 through August 28, 2025 <\/b>(the “Class Period”).<\/p>\n

\n

\n
\n \"A
\n <\/a>\n <\/p>\n<\/p><\/div>\n

\n
\n Investor Deadline:<\/i>
\n <\/b>
\n Investors who purchased Telix\u00a0securities during the Class Period may, no later than January 9, 2026<\/b>, seek to be appointed as a lead plaintiff representative of the class. To learn your rights,<\/i>\u00a0CLICK HERE<\/a><\/u><\/b>.<\/p>\n

Telix, headquartered in Melbourne, Australia, is a biopharmaceutical company specializing in radiopharmaceutical development for cancer treatment.<\/p>\n

Defendants allegedly<\/span> made false or misleading statements and\/or failed to disclose that: (1) progress on prostate cancer therapeutic candidates had been materially overstated; (2) the quality and performance of the Company’s supply chain and partners had been exaggerated; and (3) as a result, statements regarding the Company’s business, operations, and prospects were allegedly<\/span> false, misleading, or lacked a reasonable basis. When the true details became publicly known, the lawsuit alleges<\/span> that investors suffered significant losses.<\/p>\n

\n
\n If you are a Telix investor and would like to learn more about this action, <\/i>
\n <\/b>
\n
\n
\n
\n CLICK HERE<\/a>
\n <\/u>
\n <\/i>
\n <\/b>\u00a0or please contact Berger Montague: Andrew Abramowitz at <\/i><\/b>aabramowitz@bergermontague.com<\/a><\/u><\/i><\/b> or (215) 875-3015, or Caitlin Adorni at <\/i><\/b>cadorni@bergermontague.com<\/a><\/u><\/i><\/b> or (267)764-4865.<\/i><\/b><\/p>\n

\n About Berger Montague
<\/b>Berger Montague is one of the nation’s preeminent law firms focusing on complex civil litigation, class actions, and mass torts in federal and state courts throughout the United States. With more than $2.4 billion in 2025 post-trial judgments alone, the Firm is a leader in the fields of complex litigation, antitrust, consumer protection, defective products, environmental law, employment law, securities, and whistleblower cases, among many other practice areas. For over 55 years, Berger Montague has played leading roles in precedent-setting cases and has recovered over $50 billion for its clients and the classes they have represented. Berger Montague is headquartered in Philadelphia and has offices in Chicago; Malvern, PA; Minneapolis; San Diego; San Francisco; Toronto, Canada; Washington, D.C., and Wilmington, DE.<\/p>\n

\n For more information or to discuss your rights, please contact:
<\/b>Andrew Abramowitz
Senior Counsel
<\/i>Berger Montague
(215) 875-3015
aabramowitz@bergermontague.com<\/a><\/p>\n

Caitlin Adorni
Director of Portfolio & Institutional Client Monitoring Services
<\/i>Berger Montague
(267) 764-4865
cadorni@bergermontague.com<\/a><\/p>\n

\n \"Cision\" View original content to download multimedia:https:\/\/www.prnewswire.com\/news-releases\/nasdaq-tlx-investor-alert-berger-montague-advises-telix-pharmaceuticals-ltd-nasdaq-tlx-investors-of-a-january-9-2026-deadline-302642232.html<\/a><\/p>\n

SOURCE Berger Montague<\/p>\n<\/p><\/div>\n

\"\"<\/p>\n","protected":false},"excerpt":{"rendered":"

PR Newswire PHILADELPHIA, Dec. 15, 2025 \/PRNewswire\/ —\u00a0National plaintiffs’ law firm Berger Montague PC\u00a0announces that a class action lawsuit has been filed against Telix Pharmaceuticals Ltd. (NASDAQ: TLX) (“Telix” or the “Company”) on behalf of investors who purchased Telix securities during the period of\u00a0February 21, 2025 through August 28, 2025 (the “Class Period”). Investor Deadline: Investors who purchased Telix\u00a0securities during the Class Period may, no later than January 9, 2026, seek to be appointed as a lead plaintiff representative of the class. To learn your rights,\u00a0CLICK HERE. Telix, headquartered in Melbourne, Australia, is a biopharmaceutical company specializing in radiopharmaceutical development for cancer treatment. Defendants allegedly made false or misleading statements and\/or failed to disclose that: (1) progress on prostate cancer … <\/p>\n

Continue reading “NASDAQ: TLX INVESTOR ALERT: Berger Montague Advises Telix Pharmaceuticals Ltd. (NASDAQ: TLX) Investors of a January 9, 2026 Deadline”<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-919713","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"\nNASDAQ: TLX INVESTOR ALERT: Berger Montague Advises Telix Pharmaceuticals Ltd. (NASDAQ: TLX) Investors of a January 9, 2026 Deadline - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/nasdaq-tlx-investor-alert-berger-montague-advises-telix-pharmaceuticals-ltd-nasdaq-tlx-investors-of-a-january-9-2026-deadline\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"NASDAQ: TLX INVESTOR ALERT: Berger Montague Advises Telix Pharmaceuticals Ltd. (NASDAQ: TLX) Investors of a January 9, 2026 Deadline - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"PR Newswire PHILADELPHIA, Dec. 15, 2025 \/PRNewswire\/ —\u00a0National plaintiffs’ law firm Berger Montague PC\u00a0announces that a class action lawsuit has been filed against Telix Pharmaceuticals Ltd. (NASDAQ: TLX) (“Telix” or the “Company”) on behalf of investors who purchased Telix securities during the period of\u00a0February 21, 2025 through August 28, 2025 (the “Class Period”). Investor Deadline: Investors who purchased Telix\u00a0securities during the Class Period may, no later than January 9, 2026, seek to be appointed as a lead plaintiff representative of the class. To learn your rights,\u00a0CLICK HERE. Telix, headquartered in Melbourne, Australia, is a biopharmaceutical company specializing in radiopharmaceutical development for cancer treatment. Defendants allegedly made false or misleading statements and\/or failed to disclose that: (1) progress on prostate cancer … Continue reading "NASDAQ: TLX INVESTOR ALERT: Berger Montague Advises Telix Pharmaceuticals Ltd. (NASDAQ: TLX) Investors of a January 9, 2026 Deadline"\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/nasdaq-tlx-investor-alert-berger-montague-advises-telix-pharmaceuticals-ltd-nasdaq-tlx-investors-of-a-january-9-2026-deadline\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2025-12-15T14:44:15+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mma.prnewswire.com\/media\/232479\/berger_montague.jpg\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/nasdaq-tlx-investor-alert-berger-montague-advises-telix-pharmaceuticals-ltd-nasdaq-tlx-investors-of-a-january-9-2026-deadline\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/nasdaq-tlx-investor-alert-berger-montague-advises-telix-pharmaceuticals-ltd-nasdaq-tlx-investors-of-a-january-9-2026-deadline\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"NASDAQ: TLX INVESTOR ALERT: Berger Montague Advises Telix Pharmaceuticals Ltd. (NASDAQ: TLX) Investors of a January 9, 2026 Deadline\",\"datePublished\":\"2025-12-15T14:44:15+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/nasdaq-tlx-investor-alert-berger-montague-advises-telix-pharmaceuticals-ltd-nasdaq-tlx-investors-of-a-january-9-2026-deadline\\\/\"},\"wordCount\":404,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/nasdaq-tlx-investor-alert-berger-montague-advises-telix-pharmaceuticals-ltd-nasdaq-tlx-investors-of-a-january-9-2026-deadline\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mma.prnewswire.com\\\/media\\\/232479\\\/berger_montague.jpg\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/nasdaq-tlx-investor-alert-berger-montague-advises-telix-pharmaceuticals-ltd-nasdaq-tlx-investors-of-a-january-9-2026-deadline\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/nasdaq-tlx-investor-alert-berger-montague-advises-telix-pharmaceuticals-ltd-nasdaq-tlx-investors-of-a-january-9-2026-deadline\\\/\",\"name\":\"NASDAQ: TLX INVESTOR ALERT: Berger Montague Advises Telix Pharmaceuticals Ltd. (NASDAQ: TLX) Investors of a January 9, 2026 Deadline - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/nasdaq-tlx-investor-alert-berger-montague-advises-telix-pharmaceuticals-ltd-nasdaq-tlx-investors-of-a-january-9-2026-deadline\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/nasdaq-tlx-investor-alert-berger-montague-advises-telix-pharmaceuticals-ltd-nasdaq-tlx-investors-of-a-january-9-2026-deadline\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mma.prnewswire.com\\\/media\\\/232479\\\/berger_montague.jpg\",\"datePublished\":\"2025-12-15T14:44:15+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/nasdaq-tlx-investor-alert-berger-montague-advises-telix-pharmaceuticals-ltd-nasdaq-tlx-investors-of-a-january-9-2026-deadline\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/nasdaq-tlx-investor-alert-berger-montague-advises-telix-pharmaceuticals-ltd-nasdaq-tlx-investors-of-a-january-9-2026-deadline\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/nasdaq-tlx-investor-alert-berger-montague-advises-telix-pharmaceuticals-ltd-nasdaq-tlx-investors-of-a-january-9-2026-deadline\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mma.prnewswire.com\\\/media\\\/232479\\\/berger_montague.jpg\",\"contentUrl\":\"https:\\\/\\\/mma.prnewswire.com\\\/media\\\/232479\\\/berger_montague.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/nasdaq-tlx-investor-alert-berger-montague-advises-telix-pharmaceuticals-ltd-nasdaq-tlx-investors-of-a-january-9-2026-deadline\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"NASDAQ: TLX INVESTOR ALERT: Berger Montague Advises Telix Pharmaceuticals Ltd. (NASDAQ: TLX) Investors of a January 9, 2026 Deadline\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"NASDAQ: TLX INVESTOR ALERT: Berger Montague Advises Telix Pharmaceuticals Ltd. (NASDAQ: TLX) Investors of a January 9, 2026 Deadline - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/nasdaq-tlx-investor-alert-berger-montague-advises-telix-pharmaceuticals-ltd-nasdaq-tlx-investors-of-a-january-9-2026-deadline\/","og_locale":"en_US","og_type":"article","og_title":"NASDAQ: TLX INVESTOR ALERT: Berger Montague Advises Telix Pharmaceuticals Ltd. (NASDAQ: TLX) Investors of a January 9, 2026 Deadline - Market Newsdesk","og_description":"PR Newswire PHILADELPHIA, Dec. 15, 2025 \/PRNewswire\/ —\u00a0National plaintiffs’ law firm Berger Montague PC\u00a0announces that a class action lawsuit has been filed against Telix Pharmaceuticals Ltd. (NASDAQ: TLX) (“Telix” or the “Company”) on behalf of investors who purchased Telix securities during the period of\u00a0February 21, 2025 through August 28, 2025 (the “Class Period”). Investor Deadline: Investors who purchased Telix\u00a0securities during the Class Period may, no later than January 9, 2026, seek to be appointed as a lead plaintiff representative of the class. To learn your rights,\u00a0CLICK HERE. Telix, headquartered in Melbourne, Australia, is a biopharmaceutical company specializing in radiopharmaceutical development for cancer treatment. Defendants allegedly made false or misleading statements and\/or failed to disclose that: (1) progress on prostate cancer … Continue reading \"NASDAQ: TLX INVESTOR ALERT: Berger Montague Advises Telix Pharmaceuticals Ltd. (NASDAQ: TLX) Investors of a January 9, 2026 Deadline\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/nasdaq-tlx-investor-alert-berger-montague-advises-telix-pharmaceuticals-ltd-nasdaq-tlx-investors-of-a-january-9-2026-deadline\/","og_site_name":"Market Newsdesk","article_published_time":"2025-12-15T14:44:15+00:00","og_image":[{"url":"https:\/\/mma.prnewswire.com\/media\/232479\/berger_montague.jpg","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/nasdaq-tlx-investor-alert-berger-montague-advises-telix-pharmaceuticals-ltd-nasdaq-tlx-investors-of-a-january-9-2026-deadline\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/nasdaq-tlx-investor-alert-berger-montague-advises-telix-pharmaceuticals-ltd-nasdaq-tlx-investors-of-a-january-9-2026-deadline\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"NASDAQ: TLX INVESTOR ALERT: Berger Montague Advises Telix Pharmaceuticals Ltd. (NASDAQ: TLX) Investors of a January 9, 2026 Deadline","datePublished":"2025-12-15T14:44:15+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/nasdaq-tlx-investor-alert-berger-montague-advises-telix-pharmaceuticals-ltd-nasdaq-tlx-investors-of-a-january-9-2026-deadline\/"},"wordCount":404,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/nasdaq-tlx-investor-alert-berger-montague-advises-telix-pharmaceuticals-ltd-nasdaq-tlx-investors-of-a-january-9-2026-deadline\/#primaryimage"},"thumbnailUrl":"https:\/\/mma.prnewswire.com\/media\/232479\/berger_montague.jpg","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/nasdaq-tlx-investor-alert-berger-montague-advises-telix-pharmaceuticals-ltd-nasdaq-tlx-investors-of-a-january-9-2026-deadline\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/nasdaq-tlx-investor-alert-berger-montague-advises-telix-pharmaceuticals-ltd-nasdaq-tlx-investors-of-a-january-9-2026-deadline\/","name":"NASDAQ: TLX INVESTOR ALERT: Berger Montague Advises Telix Pharmaceuticals Ltd. (NASDAQ: TLX) Investors of a January 9, 2026 Deadline - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/nasdaq-tlx-investor-alert-berger-montague-advises-telix-pharmaceuticals-ltd-nasdaq-tlx-investors-of-a-january-9-2026-deadline\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/nasdaq-tlx-investor-alert-berger-montague-advises-telix-pharmaceuticals-ltd-nasdaq-tlx-investors-of-a-january-9-2026-deadline\/#primaryimage"},"thumbnailUrl":"https:\/\/mma.prnewswire.com\/media\/232479\/berger_montague.jpg","datePublished":"2025-12-15T14:44:15+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/nasdaq-tlx-investor-alert-berger-montague-advises-telix-pharmaceuticals-ltd-nasdaq-tlx-investors-of-a-january-9-2026-deadline\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/nasdaq-tlx-investor-alert-berger-montague-advises-telix-pharmaceuticals-ltd-nasdaq-tlx-investors-of-a-january-9-2026-deadline\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/nasdaq-tlx-investor-alert-berger-montague-advises-telix-pharmaceuticals-ltd-nasdaq-tlx-investors-of-a-january-9-2026-deadline\/#primaryimage","url":"https:\/\/mma.prnewswire.com\/media\/232479\/berger_montague.jpg","contentUrl":"https:\/\/mma.prnewswire.com\/media\/232479\/berger_montague.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/nasdaq-tlx-investor-alert-berger-montague-advises-telix-pharmaceuticals-ltd-nasdaq-tlx-investors-of-a-january-9-2026-deadline\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"NASDAQ: TLX INVESTOR ALERT: Berger Montague Advises Telix Pharmaceuticals Ltd. (NASDAQ: TLX) Investors of a January 9, 2026 Deadline"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/919713","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=919713"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/919713\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=919713"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=919713"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=919713"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}